Solara Active Pharma Sciences Ltd

Solara Active Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Solara Active Pharma Sciences Ltd

₹ 604 -5.83%
01 Aug - close price
solara.co.in BSE: 541540 NSE: SOLARA
About

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]

It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]

Key Points

Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]

Website BSE NSE
  • Market Cap ₹ 2,677 Cr.
  • Current Price ₹ 604
  • High / Low ₹ 886 / 441
  • Stock P/E 123
  • Book Value ₹ 304
  • Dividend Yield 0.00 %
  • ROCE 5.92 %
  • ROE -0.11 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Promoter holding has increased by 4.08% over last quarter.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -0.58% over past five years.
  • Company has a low return on equity of -11.5% over last 3 years.
  • Promoters have pledged or encumbered 39.0% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
330 338 395 381 352 425 212 299 363 347 300 273 319
320 311 349 329 333 388 374 290 321 286 243 230 262
Operating Profit 10 28 45 52 19 38 -162 10 42 61 58 43 57
OPM % 3% 8% 11% 14% 5% 9% -76% 3% 12% 18% 19% 16% 18%
6 4 7 5 2 -2 -62 -122 1 0 1 6 1
Interest 22 22 24 22 26 24 25 31 31 28 27 29 24
Depreciation 28 29 28 26 26 26 26 25 25 25 25 24 24
Profit before tax -34 -19 1 8 -30 -15 -275 -168 -12 8 8 -5 11
Tax % -44% -48% 21% 22% -34% 0% 0% 53% 0% 0% 0% 0% 0%
-19 -10 0 6 -20 -15 -275 -256 -12 8 8 -5 11
EPS in Rs -4.00 -2.06 0.09 1.35 -4.14 -3.18 -57.36 -53.42 -3.42 2.23 2.25 -1.35 2.91
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
521 1,387 1,322 1,617 1,268 1,444 1,289 1,284 1,239
462 1,173 1,065 1,232 1,187 1,309 1,384 1,080 1,021
Operating Profit 59 214 257 385 81 134 -95 204 219
OPM % 11% 15% 19% 24% 6% 9% -7% 16% 18%
2 12 27 28 14 22 -184 9 9
Interest 25 82 78 84 75 90 106 115 108
Depreciation 34 83 94 108 112 111 103 99 98
Profit before tax 2 61 112 221 -92 -45 -488 -1 22
Tax % 0% 3% 0% 0% -36% -50% 16% 0%
2 59 112 221 -59 -22 -567 -1 22
EPS in Rs 17.06 31.42 46.13 -12.20 -4.63 -118.10 -0.30 6.04
Dividend Payout % 0% 22% 5% 11% 0% -49% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -1%
3 Years: 0%
TTM: -5%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 26%
TTM: 105%
Stock Price CAGR
10 Years: %
5 Years: -6%
3 Years: 19%
1 Year: -12%
Return on Equity
10 Years: %
5 Years: -4%
3 Years: -11%
Last Year: 0%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 25 26 27 36 36 36 36 40
Reserves 745 937 1,064 1,557 1,491 1,467 901 1,056
633 538 722 621 1,037 1,013 1,012 796
414 456 339 397 373 379 398 333
Total Liabilities 1,817 1,957 2,152 2,610 2,937 2,895 2,347 2,225
1,063 1,195 1,374 1,359 1,334 1,342 1,261 1,187
CWIP 70 39 40 88 239 238 256 280
Investments 19 18 18 18 15 16 14 2
666 705 719 1,145 1,350 1,298 815 757
Total Assets 1,817 1,957 2,152 2,610 2,937 2,895 2,347 2,225

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
50 166 242 154 -242 156 111 213
-85 -113 -359 -105 -243 -81 -5 -37
67 -23 97 92 334 -113 -107 -180
Net Cash Flow 32 30 -20 142 -151 -38 -0 -5

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 185 76 63 109 141 136 99 93
Inventory Days 252 111 170 149 321 258 163 185
Days Payable 420 126 131 154 150 139 140 141
Cash Conversion Cycle 17 62 102 104 312 256 123 137
Working Capital Days -120 -20 -30 17 39 22 -129 -61
ROCE % 10% 12% 15% -1% 2% -9% 6%

Shareholding Pattern

Numbers in percentages

10 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
40.41% 40.41% 40.98% 39.31% 37.19% 30.49% 30.49% 37.27% 37.27% 37.23% 37.94% 42.01%
18.47% 19.26% 19.30% 18.71% 17.86% 16.62% 15.80% 14.00% 14.25% 14.67% 14.63% 14.25%
2.97% 3.01% 2.75% 1.75% 1.79% 1.75% 2.97% 2.83% 3.37% 3.19% 2.61% 2.62%
38.16% 37.32% 36.95% 40.22% 43.16% 51.14% 50.73% 45.89% 45.11% 44.92% 44.82% 41.10%
No. of Shareholders 83,31979,14976,32575,41774,47372,91873,91277,17071,88283,14875,79174,334

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls